The DNM1L antibody is a crucial tool for studying Dynamin-1-like protein (DNM1L), also known as DRP1. a master regulator of mitochondrial and peroxisomal fission. DNM1L is a GTPase that oligomerizes around organelle membranes to mediate membrane constriction and division. Its activity is tightly regulated by post-translational modifications (e.g., phosphorylation, SUMOylation) and interactions with adaptor proteins like MFF, MiD49. and MiD51. Dysregulation of DNM1L is linked to neurological disorders (e.g., Alzheimer’s, Parkinson’s), metabolic diseases, and cancer. DNM1L antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to assess protein expression, subcellular localization, and interactions. They help elucidate DNM1L’s role in maintaining organelle dynamics, apoptosis, and cellular energy homeostasis. Commercial DNM1L antibodies are typically raised against epitopes in the variable N-terminal or conserved GTPase domain, with validation in knockout models to ensure specificity. Researchers rely on these antibodies to explore therapeutic strategies targeting mitochondrial fragmentation in disease contexts.